PRESS RELEASE

CE mark and FDA clearance in the United States for new JAZZ diameters

Extension of the JAZZ Band™ technological platform: from a single 5.5 mm diameter implant to the market's most comprehensive range of sublaminar implants

Bordeaux, Boston, May 19, 2015 – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces that it has obtained regulatory clearance from the FDA (Food and Drug Administration) to market its 3.5 mm, 4.0 mm, 4.5 mm and 6 mm JAZZ rods in the United States and the CE mark in Europe, in addition to the original 5.5 mm diameter rod clearance.

A milestone in Implanet's development strategy, this clearance addresses the treatment of adolescent scoliosis, the first clinical indication targeted by the Company, but also in the treatment of deformity and degenerative spinal disorders in adults. In addition to the CE mark obtained late April 2015, these clearances allow JAZZ to now be a true technological platform – JAZZ Band® – comprising the most comprehensive range of sublaminar implants on the market, providing surgeons rod diameter flexibility depending on the disorders being treated.

Ludovic Lastennet, CEO of Implanet, says: "*The implanting of more than 6,000 JAZZ devices in a single 5.5 mm diameter version since its launch in late 2013 is an impressive achievement for the Company. Reaching this latest regulatory milestone will enable us to better serve our customers with a comprehensive product range and to accelerate our deployment, not only in the United States but also across all global markets. We now have major clinical, commercial and economic arguments supporting this comprehensive range. Multiple papers published in 2015 substantiate JAZZ's clinical efficacy. Our proprietary single-screw design ensures a robust attachment without any initiation of a rupture of the braid, controlled during traction by a simple and highly-efficient tensioning instrument. Lastly, a medico-economic study published in March, initiated by an independent agency, confirmed the economic benefit of hybrid constructs consisting of screws and sublaminar implants. This economic advantage, combined with a comprehensive range of JAZZ implants, should enable us to achieve our objectives in a global environment where healthcare expenses are subject to more and more stringent controls.*"

As a reminder, the results of two major studies have been published in recent months that have strengthened the value of the JAZZ technological platform in the treatment of scoliosis.

Next financial press release: revenue for the 1st half of 2015, on July 28, 2015







About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surge Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.
Ticker: IMPL - ISIN code: FR0010458729

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (0)5 57 99 55 55
investors@implanet.com

NewCap
Investor Relations
Florent Alba
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr

NewCap
Press Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 98
implanet@newcap.fr